Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.

Details

Serval ID
serval:BIB_0574C291DD4C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Patients' preferences for anti-osteoporosis drug treatment: a cross-European discrete choice experiment.
Journal
Rheumatology
Author(s)
Hiligsmann M., Dellaert B.G., Dirksen C.D., Watson V., Bours S., Goemaere S., Reginster J.Y., Roux C., McGowan B., Silke C., Whelan B., Diez-Perez A., Torres E., Papadakis G., Rizzoli R., Cooper C., Pearson G., Boonen A.
ISSN
1462-0332 (Electronic)
ISSN-L
1462-0324
Publication state
Published
Issued date
06/04/2017
Peer-reviewed
Oui
Volume
56
Number
7
Pages
1167-1176
Language
english
Notes
Publication types: Journal Article

Abstract
To estimate the preferences of osteoporotic patients for medication attributes, and analyse data from seven European countries.
A discrete choice experiment was conducted in Belgium, France, Ireland, the Netherlands, Spain, Switzerland and the UK. Patients were asked to choose repeatedly between two hypothetical unlabelled drug treatments (and an opt-out option) that varied with respect to four attributes: efficacy in reducing the risk of fracture, type of potential common side effects, and mode and frequency of administration. In those countries in which patients contribute to the cost of their treatment directly, a fifth attribute was added: out-of-pocket cost. A mixed logit panel model was used to estimate patients' preferences.
In total, 1124 patients completed the experiment, with a sample of between 98 and 257 patients per country. In all countries, patients preferred treatment with higher effectiveness, and 6-monthly subcutaneous injection was always preferred over weekly oral tablets. In five countries, patients also preferred a monthly oral tablet and yearly i.v. injections over weekly oral tablets. In the three countries where the out-of-pocket cost was included as an attribute, lower costs significantly contributed to the treatment preference. Between countries, there were statistically significant differences for 13 out of 42 attribute/level interactions.
We found statistically significant differences in patients' preferences for anti-osteoporosis medications between countries, especially for the mode of administration. Our findings emphasized that international treatment recommendations should allow for local adaptation, and that understanding individual preferences is important if we want to improve the quality of clinical care for patients with osteoporosis.

Keywords
cross-country comparison, discrete choice experiment, drug treatment, osteoporosis, patients, preferences
Pubmed
Web of science
Open Access
Yes
Create date
25/04/2017 17:28
Last modification date
20/08/2019 13:27
Usage data